Results 131 to 140 of about 2,882,240 (203)

Integrase activities: 3′-processing and DNA strand transfer by IN variants.

, 2013
Products of 3′-processing and strand transfer of the synthetic DNA duplexes with 32P-labeled B-strands (Table 1) by the consensus HIV-1 clade A integrase (IN_a), its inactivated variant (IN_in), and the inactivated variant with elvitegravir resistance ...
Elizaveta Starodubova (411353), Tomas Dillenbeck (411361), Igor M. Belyakov (411364), Linda Kostic (411355), Eva Gelius (411360), Olga Krotova (411352), Julia Agapkina (411356), Vladimir Lukashov (411365), Maria G. Isaguliants (205666), Alecia Viklund (411358), Oleg Latyshev (411359), Stefan Petkov (411354), David Hallengärd (411357), Marina Gottikh (411363), Vadim Karpov (411362)   +14 more
core   +1 more source

Discovery of 2‑Pyridinone Aminals: A Prodrug Strategy to Advance a Second Generation of HIV‑1 Integrase Strand Transfer Inhibitors

, 2015
The search for new molecular constructs that resemble the critical two-metal binding pharmacophore required for HIV integrase strand transfer inhibition represents a vibrant area of research within drug discovery.
Pravien Abeywickrema (1503235), Mark Embrey (1503244), Timothy J. Hartingh (1503232), David A. Powell (1503226), John D. Schreier (1503220), Guillaume Barbe (1503238), Daria J. Hazuda (263416), Sangita Patel (762300), Jay Grobler (1503202), Vanessa Rada (1503211), Paul Rearden (1503250), John Sisko (1503229), Jean-François Truchon (1311060), Izzat T. Raheem (1503241), Keith P. Moore (1503190), Daniel Klein (509727), Amrith Bennet (1503193), John Wai (1503217), Michael D. Miller (253934), Thomas G. Steele (1503208), Sophie−Dorothee Clas (1503196), Min Xu (15203), Paul J. Coleman (1503205), Abbas M. Walji (1503247), Natasa Pajkovic (1503214), Michael J. Hafey (1503253), David Dubost (1503223), John M. Sanders (1503199)   +27 more
core   +1 more source

Comprehensive Analysis of HIV-1 Integrase Resistance-Related Mutations in African Countries

Pathogens
The growing emergence of non-nucleoside reverse transcriptase inhibitor (NNRTI) HIV drug resistance in sub-Saharan Africa (SSA) led to the World Health Organization (WHO) recommending, in 2018, a transition to dolutegravir (DTG) as a first-line ...
Francesco Branda, Marta Giovanetti, Leonardo Sernicola, Stefania Farcomeni, Massimo Ciccozzi, Alessandra Borsetti   +5 more
doaj   +1 more source

Inhibition of lipid synthesis by the HIV integrase strand transfer inhibitor elvitegravir in primary rat oligodendrocyte cultures. [PDF]

Front Mol Neurosci, 2023
Monnerie H, Romer M, Roth LM, Long C, Millar JS, Jordan-Sciutto KL, Grinspan JB.   +6 more
europepmc   +1 more source

Association between HIV integrase strand transfer inhibitor use and type 2 diabetes mellitus

: Following reports of widespread primary resistance to non-nucleoside reverse transcriptase inhibitors (NNRTIs), the World Health Organization (WHO) recommended dolutegravir (DTG), an integrase strand transfer inhibitor (INSTI) as an anchor drug for ...
Mulindwa, Frank
core  

No evidence of rapid reversibility of tenofovir alafenamide and/or integrase strand transfer inhibitor-associated weight gain. [PDF]

AIDS, 2023
Verburgh ML, Wit FWNM, Boyd A, Reiss P, Van der Valk M, on behalf of the ATHENA national observational cohort .   +5 more
europepmc   +1 more source

Integrase strand-transfer inhibitor use and cardiovascular events in adults with HIV: an emulation of target trials in the HIV-CAUSAL Collaboration and the Antiretroviral Therapy Cohort Collaboration. [PDF]

Lancet HIV, 2023
Rein SM, Lodi S, Logan RW, Touloumi G, Antoniadou A, Wittkop L, Bonnet F, van Sighem A, van der Valk M, Reiss P, Klein MB, Young J, Jarrin I, d'Arminio Monforte A, Tavelli A, Meyer L, Tran L, Gill MJ, Lang R, Surial B, Haas AD, Justice AC, Rentsch CT, Phillips A, Sabin CA, Miro JM, Trickey A, Ingle SM, Sterne JAC, Hernán MA, Antiretroviral Therapy Cohort Collaboration and the HIV-CAUSAL Collaboration.   +30 more
europepmc   +1 more source

Integrase Strand Transfer Inhibitor Use and Cancer Incidence in a Large Cohort Setting. [PDF]

Open Forum Infect Dis, 2022
Greenberg L, Ryom L, Neesgaard B, Miró JM, Dahlerup Rasmussen L, Zangerle R, Grabmeier-Pfistershammer K, Günthard HF, Kusejko K, Smith C, Mussini C, Menozzi M, Wit F, Van Der Valk M, d'Arminio Monforte A, De Wit S, Necsoi C, Pelchen-Matthews A, Lundgren J, Peters L, Castagna A, Muccini C, Vehreschild JJ, Pradier C, Bruguera Riera A, Sönnerborg A, Petoumenos K, Garges H, Rogatto F, Dedes N, Bansi-Matharu L, Mocroft A, RESPOND Study Group .   +32 more
europepmc   +1 more source

HIV RNA Screening Reduces Integrase Strand Transfer Inhibitor Resistance Risk in Persons Receiving Long-Acting Cabotegravir for HIV Prevention. [PDF]

J Infect Dis, 2022
Eshleman SH, Fogel JM, Halvas EK, Piwowar-Manning E, Marzinke MA, Kofron R, Wang Z, Mellors J, McCauley M, Rinehart AR, St Clair M, Adeyeye A, Hinojosa JC, Cabello R, Middelkoop K, Hanscom B, Cohen MS, Grinsztejn B, Landovitz RJ, HPTN 083 Study Team.   +19 more
europepmc   +1 more source

Emergence of Integrase Strand Transfer Inhibitor Resistance Following Treatment of Latent Tuberculosis Infection in a Patient With HIV. [PDF]

Open Forum Infect Dis
Dyer E, Sunagawa SW, Regan N, Davis JM, Bares SH.   +4 more
europepmc   +1 more source